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Objectives: Different jurisdictions organize their health technology assessment 
(HTA) capacity in different ways. In theory, a centralized approach offers the poten-
tial to pool the scarce resources devoted to HTA and national recommendations can 
be issued to encourage a uniform development of services across the whole country. 
On the other hand, a regional approach could help in tailoring recommendations to 
local needs. The objective of this study was to compare the assessment procedures 
in England (centralized approach) with Spain (regional approach). MethOds: We 
compared the assessments of the same cancer drugs in the two jurisdictions from 
2000 to 2015, extracting data on the availability of an HTA, the indication(s) studied, 
the comparator(s) considered, the cost-effectiveness assessments produced and the 
reimbursement recommendation (recommended with no restrictions, optimized 
or denied use). Results: The indications studied and the comparators considered 
were similar in the two jurisdictions. In England an HTA with a cost-effectiveness 
estimate was available for 105 drug/indication pairings: recommended (32%), opti-
mized(30%) and denied(38%). The Spanish HTA for pharmaceuticals is characterized 
by a high decentralization and lack of coordination. Decisions at national level 
were based on effectiveness and safety but no clear recommendations were made. 
Therefore we used data from two regional Governments (Andalucía and Cataluña) 
and a pharmacy scientific society (SEFH) where recommendations were stronger and 
considered cost-effectiveness. For the period of 2011-2014 a total of 43 indications 
were assessed in Cataluña: optimized (86%) exceptional use (14%). cOnclusiOns: 
Due to a relative lack of central coordination, the approach to HTA in Spain leads 
to a less standardized approach for technology assessments of cancer drugs than 
in England. In addition, cost-effectiveness evidence is less frequently generated. 
However, a lower proportion of drugs receive a negative recommendation, which 
may reflect both the lower level of cost-effectiveness scrutiny and a relatively higher 
willingness-to-pay.
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Objectives: To evaluate whether scores from paper (P) and electronic tablet (E) 
versions of seven PRO measures [SF-36v2 Health Survey (Standard), Bath Ankylosing 
Spondylitis Disease Activity Index, Health Assessment Questionnaire, Dermatology 
Quality of Life Instrument, Patient Global Assessment of Disease Activity, Subject 
Assessment of Pain, and, Fatigue Visual Analogue Scale are equivalent. MethOds: 
After establishing that patients interpreted P and E instruments in similar ways 
using cognitive interviews, a crossover study was conducted in 53 patients (34 
women) aged 18-83 years. A three-period design was used, with the first two peri-
ods being E and P in randomised order, the third period being P for all patients. This 
allowed both P-E and P-P reliabilities to be compared. Patients’ opinions on ease of 
use and acceptability of the electronic version were collected. Results: Intraclass 
Correlation Coefficients ranged from 0.75 to 0.97, all above the generally accepted 
threshold of .70. Correlations were in general similar for P-E (mode equivalence) 
and P-P (test-retest reliability for paper|) T-tests revealed no significant mean dif-
ference between P and E scores. Mean score differences between P and E measures 
were small and within an acceptable limit of equivalence. The majority of patients 
reported that the electronic tablet was acceptable (99%), and ‘very easy’ (81.8%) or 
‘quite easy’ (14.3%) to use. Few subjects (5%) reported problems using the tablet. The 
majority of patients (37; 74%) preferred the tablet version to paper, while 12 (24%) 
had no preference, and 1 (2%) preferred paper. cOnclusiOns: Results indicate 
that the PRO scores are equivalent when administered to patients with PsA via 
electronic and paper modes. The tablet versions were easy and acceptable to use, 
and preferred over paper versions. These results support the use of the electronic 
tablet versions of the PRO measures in PsA clinical trials.
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Objectives: Understanding the meaning of differences in HRQL scores is essential 
in communicating the value of treatment to stakeholders. This study translates 
differences in scores from a widely used HRQL measure, the SF-12v2, into differ-
ences in future medical expenditures across 5 major conditions. MethOds: Data 
came from the Medical Expenditures Panel Survey (MEPS; n= 20,624), collected in 
2006/2007. Conditions were identified by associated medical events, disability days 
or self-report. Medical expenditures (MEs) were calculated as the sum of payments 
for prescription medicines, hospital inpatient, emergency room, out-patient and 
office-based provider visits in the 6 months following administration of the SF-12v2. 
We modeled the effect of physical (PCS) and mental (MCS) component summary 
scores on MEs using logit-gamma two-part models that controlled for age, gender, 
marital status, comorbidities count and insurance status. Results: A 5-point lower 
PCS score was associated with a 22% increase in MEs among people with asthma and 
diabetes, 18% increase in migraine, 17% increase in depression and 14% increase in 
arthritis. 5-point lower MCS score was associated with a 9% increase in MEs among 
people with diabetes, 8% increase in migraine, 7% increase in arthritis and asthma 
and 4% in depression. The effect of PCS on MEs decreased with age in arthritis 
(P= 0.0210) and similarly for MCS in depression (P= 0.0365). A 5-point lower PCS was 
associated with a 25% increase in MEs in arthritis at age 45 but a 14% increase at age 
areas of the health care system. A critical appraisal was done covering the public HTA 
reports and the decisions for reimbursement of new therapies. Results: The HTA 
implementation started in 2013, but the first model of a scorecard HTA was abrogated 
in April 2014. From July 2014 the HTA responsibility moved at the National Drugs 
Agency and a new scorecard model was introduced. The Romanian HTA system is a 
quick-HTA based on a scorecard which sums up to 145 points, the criteria being: HAS 
(France) evaluation, NICE/SMC (UK) evaluation, IQWIG/G-BA (Germany) evaluation, the 
number of EU countries with reimbursement, the RWD study and the Budget Impact 
Analysis. There are two thresholds: over 80 points for unconditional reimbursement 
and 60-79 points for conditional reimbursements. By the end of 2014 were evaluated 
174 dossiers, including new INNs, new indications and new fixed dose combination. 
After the appeals done by MAHs, 23 new INNs were unconditionally included in the 
List and 51 INNs scored for conditional reimbursement, waiting for the cost-volume 
contracts to be signed in second semester of 2015. cOnclusiOns: The introduction 
of the scorecard HTA in Romania created the possibility to access for new drugs, in a 
transparent and objective manner, for the first time since 2008. The system does not 
require any cost-effectiveness model and has a predominant budget impact perspec-
tive for unconditional reimbursement, but created the circumstances to access on 
the List using commercial arrangements.
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Objectives: The Health Information and Quality Authority (HIQA) is a statutory, 
government-funded agency in Ireland which monitors the safety and quality of 
the healthcare and social care systems. HIQA has approximately 210 staff, with 7 
working in HTA. Since 2010 we have completed 7 full HTAs and 25 rapid HTAs in 
addition to 6 national HTA guidelines. This study sought to evaluate the impact 
of a national HTA. MethOds: In 2013 the Minister for Health requested that we 
examine the implications of establishing a national public access defibrillation 
(PAD) programme in Ireland to increase survival from out-of-hospital cardiac 
http://www.hiqa.ie/healthcare/health-technology-assessment/assessments/hta-
public-access-defibrillation. We sought to measure impact by analysing activity 
under four headings: internal processes; relevance of activity; value of activity; and 
communication of activity. Semi-structured questionnaires were circulated to key 
stakeholders for feedback. Results: Stakeholders indicated that they were happy 
with the management of the project and their opportunities to input into the HTA. 
The methodology used for the evaluation followed best practice, with the model 
reviewed by an external expert. The HTA was explicitly linked to a decision, and 
was found to strongly influence policy. The HTA took 308 person days to complete 
at an estimated cost of € 172,000. Public consultation resulted in over 100 comments 
from 20 individuals or organisations. The report was downloaded 502 times. There 
was greater activity associated with the public consultation version than with the 
final version. cOnclusiOns: The direct link to a policy decision meant that the 
HTA was likely to have high impact, this was supported by the scientific integrity of 
the report. The cost of producing the HTA compared favourably with, for example, 
NIHR funding for full HTAs in the UK. Where public consultation leads to changes in 
a report, it may be necessary to actively increase awareness of the final publication.
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Objectives: Health Technology Assessment (HTA) is the basis for drug reim-
bursement in many countries, however, it is not always clear how different factors 
are incorporated and weighted by HTA bodies. This research aims to develop a 
model that identifies the drivers of successful HTA submission in five European 
HTA agencies. MethOds: Single drug assessments conducted between January 
2011 and April 2015 were extracted from a database of HTA evaluations. The HTA 
outcome (recommendation for National Institute for Health and Care Excellence 
(NICE), Scottish Medicines Consortium (SMC) and Zorginstituut Nederland (ZIN); 
‘Amélioration du service médical rendu’ (ASMR) for Haute Autorité de Santé (HAS) 
and benefit rating for Gemeinsamer Bundesausschuss (G-BA)) and the clinical, 
economic and societal data underlying the assessment were collected. Factors 
influencing the outcome were determined by univariate and multivariate analy-
ses. Results: In total, 1019 HTAs were identified: 108 for G-BA, 464 for HAS, 68 for 
NICE, 218 for SMC and 69 for ZIN. Each model started with 63 explanatory variables, 
which were then refined by omitting variables that showed many missing values. A 
backward regression model was used to develop the models with the best fit. Models 
were chosen following several tests of goodness of fit: Akaike information criterion 
(AIC), likelihood-ratio, Wald-test and residual chi-square, resulting in country-spe-
cific models that predict factors with the best fit. cOnclusiOns: Univariate and 
multivariate backward regressions were used to develop models for understand-
ing the key drivers of HTA recommendations. In most countries, clinical factors 
appeared to be predictive factors for success. In countries performing economic 
evaluations, mainly economic factors appeared to be predictive factors. Societal 
factors were identified less frequently as predictive factors for recommendation. 
The difference in observations per country was a limitation for this research. Further 
research could expand the time horizon in order to increase the observations.
ht4
regional versus centralized hta: implications for the assessment 
of cancer drugs
Corbacho B1, Drummond M1, Jones E2, Espin J3, Expósito Hernandez J4, Borras JM5
1University of York, Heslington, York, UK, 2MAPI, Uxbridge, UK, 3Andalusian School of Public 
Health, Granada, Spain, 4Instituto de Investigación Biosanitaria Ibs, Granada, Spain, 5University 
of Barcelona, Hospitalet, Spain
